Compare Cytokinetics Inc (CYTK) vs KB Financial Group, Inc. (KB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs KB Financial Group, Inc. — how do they compare? Cytokinetics Inc trades at $62.1 (market cap $8.62B), while KB Financial Group, Inc. trades at $122 (market cap $42.62B). The key difference: KB Financial Group, Inc. is far larger — about 4.9× Cytokinetics Inc's market cap, and KB Financial Group, Inc. pays a 2.71% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and KB Financial Group, Inc. for 33 Days on average.
| CYTK | KB | |
|---|---|---|
Market Cap | $8.62B | $42.62B |
Volume | 2,594,626 | 164,291 |
Sector | Health | Financials |
52-Week High | $87.26 | $132.88 |
52-Week Low | $54.76 | $77.50 |
Typical Hold Time | 19 Days | 33 Days |
Enterprise Value | $8.72B | $215.53T |
Dividend Yield | — | 2.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
KB Financial Group (KB) trades at $124.73, showing minimal daily movement with a slight decline of 0.02%. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and improving profitability metrics. Technical indicators suggest a neutral near-term outlook, while analyst sentiment leans cautious with a 66.7% hold rating. Recent news highlights institutional interest and positive momentum coverage from financial media.
The outlook for KB appears balanced with attractive valuation metrics including a P/E of 9.68 and P/B of 0.94 suggesting potential undervaluation. However, the mixed analyst consensus and elevated EV/EBITDA of 21.71 warrant caution. Key risks include exposure to South Korean economic conditions and banking sector volatility, while opportunities lie in continued earnings growth and dividend potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →
